KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Long-Term Debt Repayments (2021 - 2023)

Halozyme Therapeutics (HALO) has disclosed Long-Term Debt Repayments for 3 consecutive years, with -$13.5 million as the latest value for Q4 2023.

  • Quarterly Long-Term Debt Repayments rose 68.31% to -$13.5 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$13.5 million through Sep 2024, up 53.61% year-over-year, with the annual reading at $250.0 million for FY2025, N/A changed from the prior year.
  • Long-Term Debt Repayments for Q4 2023 was -$13.5 million at Halozyme Therapeutics, down from -$17000.0 in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $369.1 million in Q1 2021, with the low at -$42.5 million in Q4 2022.
  • Average Long-Term Debt Repayments over 3 years is $115.9 million, with a median of $6.7 million recorded in 2023.
  • The sharpest move saw Long-Term Debt Repayments tumbled 111.53% in 2022, then skyrocketed 68.31% in 2023.
  • Over 3 years, Long-Term Debt Repayments stood at $369.1 million in 2021, then tumbled by 111.53% to -$42.5 million in 2022, then surged by 68.31% to -$13.5 million in 2023.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at -$13.5 million, -$17000.0, and $13.5 million for Q4 2023, Q2 2023, and Q1 2023 respectively.